Digoxin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Adult Dosing == | ==General== | ||
*Type: | |||
*Dosage Forms: | |||
*Common Trade Names: | |||
==Adult Dosing== | |||
*Loading dose = 0.25 mg IV q2hr until effect (max total = 1.5 mg) | *Loading dose = 0.25 mg IV q2hr until effect (max total = 1.5 mg) | ||
*in acute afib rvr with heart failure = 0.5 mg IV, then 0.25 mg IV q4hr until effect or max 1.5mg | *in acute afib rvr with heart failure = 0.5 mg IV, then 0.25 mg IV q4hr until effect or max 1.5mg | ||
== | ==Pediatric Dosing== | ||
* | |||
** | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | |||
*[[Lactation risk categories|Lactation risk]]: | |||
*Renal Dosing | |||
**Adult | |||
**Pediatric | |||
*Hepatic Dosing | |||
**Adult | |||
**Pediatric | |||
== Indications == | == Indications == | ||
*RVR control in a-fib/flutter, PSVT | *RVR control in a-fib/flutter, PSVT | ||
== | ==Contraindications== | ||
* | *Allergy to class/drug | ||
* | *[[WPW]] | ||
**Increases conduction velocity in atrial tissue | |||
** | |||
== Adverse | ==Adverse Reactions== | ||
*GI: N/V, diarrhea, abd pain | *GI: N/V, diarrhea, abd pain | ||
*CV: Bradycardia, SA/AV block, ventr arrhythmias | *CV: Bradycardia, SA/AV block, ventr arrhythmias | ||
== | ==Pharmacology== | ||
*Onset of action = 1.5-4hr (IV) | *Half-life: | ||
*Metabolism: | |||
*Excretion: | |||
*Mechanism of Action: | |||
**Inhibits NaK pump | |||
***Positive inotropy | |||
**Negative chronotropy/dromotropy | |||
***Indirect vagal stimulator | |||
*Kinetics | |||
**Onset of action = 1.5-4hr (IV) | |||
==Comments== | |||
==See Also== | ==See Also== | ||
| Line 27: | Line 50: | ||
*[[Antiarrhythmics]] | *[[Antiarrhythmics]] | ||
==References== | |||
<references/> | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 13:22, 10 June 2015
General
- Type:
- Dosage Forms:
- Common Trade Names:
Adult Dosing
- Loading dose = 0.25 mg IV q2hr until effect (max total = 1.5 mg)
- in acute afib rvr with heart failure = 0.5 mg IV, then 0.25 mg IV q4hr until effect or max 1.5mg
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation risk:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Indications
- RVR control in a-fib/flutter, PSVT
Contraindications
- Allergy to class/drug
- WPW
- Increases conduction velocity in atrial tissue
Adverse Reactions
- GI: N/V, diarrhea, abd pain
- CV: Bradycardia, SA/AV block, ventr arrhythmias
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
- Inhibits NaK pump
- Positive inotropy
- Negative chronotropy/dromotropy
- Indirect vagal stimulator
- Inhibits NaK pump
- Kinetics
- Onset of action = 1.5-4hr (IV)
